NDAs: Impurities in Drug Substances
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
February 1, 2000
April 28, 2022
9a9aed41-ecdb-4d76-ae37-eed05ef236c6
Related Documents
Levothyroxine Sodium Tablets - In Vivo Pharmacokinetic and Bioavailability Studies and In Vitro Dissolution Testing
Guidance DocumentMarch 8, 2001Center for Drug Evaluation and Research
Alternate Source of the Active Pharmaceutical Ingredient in Pending ANDAs: Guidance for Industry
Guidance DocumentDecember 1, 2000Center for Drug Evaluation and Research
Drug Master Files for Bulk Antibiotic Drug Substances: Guidance for Industry
Guidance DocumentNovember 29, 1999Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Stay ahead of FDA enforcement
New KeyPedia insights, webinars, and regulatory analysis — straight to your inbox. Unsubscribe anytime.